Scynexis. has filed a patent for enfumafungin derivative triterpenoid antifungal compounds that are effective in treating fungal infections under acidic conditions with a pH lower than 7. These compounds inhibit (1,3)-ß-D-glucan synthesis and are useful in treating infections in low pH areas like the vaginal cavity. GlobalData’s report on Scynexis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Scynexis Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Scynexis, Peptide pharmacophores was a key innovation area identified from patents. Scynexis's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of fungal infections with enfumafungin derivative triterpenoids

Source: United States Patent and Trademark Office (USPTO). Credit: Scynexis Inc

A recently filed patent (Publication Number: US20230364067A1) discloses a method for treating fungal infections in individuals in need of medical intervention. The method involves administering a specific compound, or a pharmaceutically acceptable salt thereof, to the subject. The compound is defined by a specific chemical formula (Formula I) and includes various substituents such as C1-C3 alkyl groups and heteroaryl rings containing nitrogen atoms. Importantly, the treatment is targeted towards fungal infections caused by yeast or mold, occurring in environments with a pH lower than about 7.

Furthermore, the patent outlines the administration methods for the compound or its salt, which can be done either topically or via intra-lesional injection. The treatment is specifically designed for fungal infections such as fungal abscess, empyema, and infections of the upper gastrointestinal tract. By targeting these specific types of fungal infections in individuals with lower pH environments, the method aims to provide an effective and targeted treatment option for patients in need of fungal infection management.

To know more about GlobalData’s detailed insights on Scynexis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies